Stockreport

Capricor's cell therapy shows three year benefit in DMD patients [Yahoo! Finance]

Capricor Therapeutics, Inc.  (CAPR) 
Last capricor therapeutics, inc. earnings: 3/18 04:01 pm Check Earnings Report
US:NASDAQ Investor Relations: capricor.com/investors
PDF The Phase II (NCT03406780) three-year open-label extension (OLE) study showed that deramiocel led to a 47% slowing of disease in skeletal muscle in patients with DMD. [Read more]